KMG Fiduciary Partners LLC Acquires 39,875 Shares of Pfizer Inc. $PFE

KMG Fiduciary Partners LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 26.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,888 shares of the biopharmaceutical company’s stock after purchasing an additional 39,875 shares during the period. KMG Fiduciary Partners LLC’s holdings in Pfizer were worth $4,597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its position in Pfizer by 26.5% in the 2nd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 16,031 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 3,359 shares during the period. Perkins Coie Trust Co boosted its position in Pfizer by 1.2% during the second quarter. Perkins Coie Trust Co now owns 63,473 shares of the biopharmaceutical company’s stock valued at $1,528,000 after purchasing an additional 747 shares in the last quarter. Fulton Bank N.A. lifted its position in shares of Pfizer by 7.7% during the second quarter. Fulton Bank N.A. now owns 128,183 shares of the biopharmaceutical company’s stock valued at $3,087,000 after buying an additional 9,162 shares during the last quarter. First Bank & Trust boosted its holdings in shares of Pfizer by 3.3% in the 2nd quarter. First Bank & Trust now owns 265,755 shares of the biopharmaceutical company’s stock valued at $6,399,000 after buying an additional 8,373 shares in the last quarter. Finally, Shrier Wealth Management LLC grew its position in shares of Pfizer by 1.8% in the 2nd quarter. Shrier Wealth Management LLC now owns 44,811 shares of the biopharmaceutical company’s stock worth $1,079,000 after buying an additional 791 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. JPMorgan Chase & Co. cut their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. BMO Capital Markets lowered their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Trading Up 1.0%

Pfizer stock opened at $27.04 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The company has a market capitalization of $154.12 billion, a price-to-earnings ratio of 35.58 and a beta of 0.34. The stock has a 50-day moving average price of $25.05 and a 200 day moving average price of $26.18.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.97 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is currently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.